Genetic profiling in graves' disease: Further evidence for lack of a distinct genetic contribution to graves' ophthalmopathy

Thyroid

Volumn 22, Issue 7, 2012, Pages 730-736

  Yin, Xiaoming ^a   Latif, Rauf ^a   Bahn, Rebecca ^b   Davies, Terry F ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR3 ANTIGEN; INTERLEUKIN 23 RECEPTOR; THYROTROPIN RECEPTOR;

ARTICLE; DECOMPRESSION SURGERY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CTLA-4 ANTIGEN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HLA-DR3 ANTIGEN; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN; RECEPTORS, THYROTROPIN;

EID: 84863430260     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0007     Document Type: Article

References (58)

1. Jacobson DL, Gange SJ, Rose NR, Graham NM 1997 Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84:223-243.
2. Weetman AP 2000 Graves? disease. N. Engl. J. Med 343: 1236-1248.
3. Khoo TK, Bahn RS 2007 Pathogenesis of Graves? ophthalmopathy: The role of autoantibodies. Thyroid 17:1013-1018.
4. El-Kaissi S, Frauman AG, Wall JR 2004 Thyroid-Associated ophthalmopathy: A practical guide to classification, natural history and management. Intern Med J 34:482-491.
5. Valyasevi RW, Jyonouchi SC, Dutton CM, Munsakul N, Bahn RS 2001 Effect of tumor necrosis factor-Alpha, interferon-gamma, and transforming growth factor-beta on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 86:903-908.
6. Gianoukakis AG, Khadavi N, Smith TJ 2008 Cytokines, Graves? disease, and thyroid-Associated ophthalmopathy. Thyroid 18:953-958.
7. Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM, Toft AD, McCarthy MI, Kendall-Taylor P, Pearce SH 1999 The cytotoxic T lymphocyte antigen-4 is a major Graves? disease locus. Hum Mol Genet 8:1195-1199.
8. Jacobson EM, Huber A, Tomer Y 2008 The HLA gene complex in thyroid autoimmunity: From epidemiology to etiology. J Autoimmun 30:58-62.
9. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ 1995 CTLA-4 gene polymorphism associated with Graves? disease in a Caucasian population. J Clin Endocrinol Metab 80:41-45.
10. Kavvoura FK, Akamizu T, Awata T, Ban Y, Chistiakov DA, Frydecka I, Ghaderi A, Gough SC, Hiromatsu Y, Ploski R, Wang PW, Bednarczuk T, Chistiakova EI, Chojm M, Heward JM, Hiratani H, Juo SH, Karabon L, Katayama S, Kurihara S, Liu RT, Miyake I, Omrani GH, Pawlak E, Taniyama M, Tozaki T, Ioannidis JP 2007 Cytotoxic Tlymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: A meta-Analysis. J Clin Endocrinol Metab 92:3162-3170.
11. Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, Donaldson PT, Ball SG, James RA, Quinton R, Perros P, Pearce SH 2004 The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves? disease. J Clin Endocrinol Metab 89:5862-5865.
12. Zhang J, Zahir N, Jiang Q, Miliotis H, Heyraud S, Meng X, Dong B, Xie G, Qiu F, Hao Z, McCulloch CA, Keystone EC, Peterson AC, Siminovitch KA 2011 The autoimmune disease-Associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 43:902-907.
13. Tomer Y, Concepcion E, Greenberg DA 2002 A C/T singlenucleotide polymorphism in the region of the CD40 gene is associated with Graves? disease. Thyroid 12:1129-1135.
14. Jacobson EM, Tomer Y 2007 The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: Back to the future. J Autoimmun 28:85-98.
15. Brand OJ, Lowe CE, Heward JM, Franklyn JA, Cooper JD, Todd JA, Gough SC 2007 Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves? disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf ) 66:508-512.
16. Chistiakov DA, Chistiakova EI, Voronova NV, Turakulov RI, Savost?anov KV 2011 A variant of the IL2RA/CD25 gene predisposing to Graves? disease is associated with increased levels of soluble interleukin-2 receptor. Scand J Immunol 74:496-501.
17. Kochi Y, Yamada R, Suzuki A, Harley JB, Shirasawa S, Sawada T, Bae SC, Tokuhiro S, Chang X, Sekine A, Takahashi A, Tsunoda T, Ohnishi Y, Kaufman KM, Kang CP, Kang C, Otsubo S, Yumura W, Mimori A, Koike T, Nakamura Y, Sasazuki T, Yamamoto K 2005 A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet 37:478-485.
18. Gu LQ, Zhu W, Zhao SX, Zhao L, Zhang MJ, Cui B, Song HD, Ning G, Zhao YJ 2010 Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves? disease. Clin Endocrinol (Oxf ) 72:248-255.
19. Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y 2008 Interleukin (IL)-23 receptor is a major susceptibility gene for Graves? ophthalmopathy: The IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 93:1077-1081.
20. Ho SC, Goh SS, Khoo DH 2003 Association of Graves? disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins. Thyroid 13:523-528.
21. Hiratani H, Bowden DW, Ikegami S, Shirasawa S, Shimizu A, Iwatani Y, Akamizu T 2005 Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves? disease. J Clin Endocrinol Metab 90:2898-2903.
22. Dechairo BM, Zabaneh D, Collins J, Brand O, Dawson GJ, Green AP, Mackay I, Franklyn JA, Connell JM, Wass JA, Wiersinga WM, Hegedus L, Brix T, Robinson BG, Hunt PJ, Weetman AP, Carey AH, Gough SC 2005 Association of the TSHR gene with Graves? disease: The first disease specific locus. Eur J Hum Genet 13:1223-1230.
23. Yin X, Latif R, Bahn R, Tomer Y, Davies TF 2008 Influence of the TSH receptor gene on susceptibility to Graves? disease and Graves? ophthalmopathy. Thyroid 18:1201-1206.
24. Colobran R, Armengol Mdel P, Faner R, Gartner M, Tykocinski LO, Lucas A, Ruiz M, Juan M, Kyewski B, Pujol-Borrell R 2011 Association of an SNP with intrathymic transcription of TSHR and Graves? disease: A role for defective thymic tolerance. Hum Mol Genet 20:3415-3423.
25. Tomer Y, Greenberg DA, Concepcion E, Ban Y, Davies TF 2002 Thyroglobulin is a thyroid specific gene for the familial autoimmune thyroid diseases. J Clin Endocrinol Metab 87:404-407.
26. Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, Conception E, Fadlalla M, Ho K, Tomer Y 2011 Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon {alpha}-modulated mechanism. J Biol Chem 286:31168-31179.
27. Villanueva R, Inzerillo AM, Tomer Y, Barbesino G, Meltzer M, Concepcion ES, Greenberg DA, MacLaren N, Sun ZS, Zhang DM, Tucci S, Davies TF 2000 Limited genetic susceptibility to severe Graves? ophthalmopathy: No role for CTLA-4 but evidence for an environmental etiology. Thyroid 10:791-798.
28. Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy MI, Kendall-Taylor P, Pearce SH 1999 Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet 354:743-744.
29. Werner SC 1977 Modification of the classification of the eye changes of Graves? disease: Recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 44:203-204.
30. Kloprogge S, Kowal L, Wall J, Frauman AG 2005 The clinicopathologic basis of Graves? ophthalmopathy: A review. Eur J Ophthalmol 15:315-323.
31. Westman P, Kuismin T, Partanen J, Koskimies S 1993 An HLADR typing protocol using group-specific PCR-Amplification followed by restriction enzyme digests. Eur J Immunogenet 20:103-109.
32. Tomer Y, Greenberg DA, Barbesino G, Concepcion E, Davies TF 2001 CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 86:1687-1693.
33. Yin X, Latif R, Tomer Y, Davies TF 2007 Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann NY Acad Sci 1110:193-200.
34. Tomer Y 2010 Genetic susceptibility to autoimmune thyroid disease: Past, present, and future. Thyroid 20:715-725.
35. Davies TF, Yin X, Latif R 2010 The genetics of the thyroid stimulating hormone receptor: History and relevance. Thyroid 20:727-736.
36. Davies TF, Latif R, Yin X 2009 Inheriting autoimmune thyroid disease. Endocr Pract 15:63-66.
37. Wiebolt J, Koeleman BP, van Haeften TW 2010 Endocrine autoimmune disease: Genetics become complex. Eur J Clin Invest 40:1144-1155.
38. Davies TF 2007 Really significant genes for autoimmune thyroid disease do not exist-so how can we predict disease? Thyroid 17:1027-1029.
39. Bartalena L 2005 Editorial: Glucocorticoids for Graves? ophthalmopathy: How and when. J Clin Endocrinol Metab 90:5497-5499.
40. Bahn RS 2010 Graves? ophthalmopathy. N. Engl. J. Med 362: 726-738.
41. Eckstein AK, Johnson KT, Thanos M, Esser J, Ludgate M 2009 Current insights into the pathogenesis of Graves? orbitopathy. Horm Metab Res 41:456-464.
42. Rapoport B, Alsabeh R, Aftergood D, McLachlan SM 2000 Elephantiasic pretibial myxedema: Insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves? disease. Thyroid 10:685-692.
43. Jacobson DH, Gorman CA 1984 Endocrine ophthalmopathy: Current ideas concerning etiology, pathogenesis, and treatment. Endocr Rev 5:200-220.
44. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves? ophthalmopathy: Reality and perspectives. Endocr Rev 21:168-199.
45. Allahabadia A, Heward JM, Nithiyananthan R, Gibson SM, Reuser TT, Dodson PM, Franklyn JA, Gough SC 2001 MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves? disease. Lancet 358:984-985.
46. Petrone A, Giorgi G, Galgani A, Alemanno I, Corsello SM, Signore A, Di Mario U, Nistico L, Cascino I, Buzzetti R 2005 CT60 single nucleotide polymorphisms of the cytotoxic Tlymphocyte-Associated antigen-4 gene region is associated with Graves? disease in an Italian population. Thyroid 15:232-238.
47. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH 2006 A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461-1463.
48. Farago B, Magyari L, Safrany E, Csongei V, Jaromi L, Horvatovich K, Sipeky C, Maasz A, Radics J, Gyetvai A, Szekanecz Z, Czirjak L, Melegh B 2008 Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis 67:248-250.
49. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB 2007 A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasisrisk genes. Am J Hum Genet 80:273-290.
50. Safrany E, Melegh B 2009 Functional variants of the interleukin-23 receptor gene in non-gastrointestinal autoimmune diseases. Curr Med Chem 16:3766-3774.
51. Ban Y, Tozaki T, Taniyama M, Nakano Y, Yoneyama K, Hirano T 2009 Association studies of the IL-23R gene in autoimmune thyroid disease in the Japanese population. Autoimmunity 42:126-130.
52. Tomer Y, Davies TF 2003 Searching for the autoimmune thyroid disease susceptibility genes: From gene mapping to gene function. Endocr Rev 24:694-717.
53. Simmonds MJ, Howson JM, Heward JM, Carr-Smith J, Franklyn JA, Todd JA, Gough SC 2007 A novel and major association of HLA-C in Graves? disease that eclipses the classical HLA-DRB1 effect. Hum Mol Genet 16:2149-2153.
54. Frecker M, Mercer G, Skanes VM, Farid NR 1988 Major histocompatibility complex (MHC) factors predisposing to and protecting against Graves? eye disease. Autoimmunity 1:307-315.
55. Stenszky V, Kozma L, Balazs C, Farid NR 1983 HLA-DR associations with Graves? disease in eastern Hungary. Clin Invest Med 6:181-184.
56. Weetman AP, So AK, Warner CA, Foroni L, Fells P, Shine B 1988 Immunogenetics of Graves? ophthalmopathy. Clin Endocrinol (Oxf ) 28:619-628.
57. Kendall-Taylor P, Stephenson A, Stratton A, Papiha SS, Perros P, Roberts DF 1988 Differentiation of autoimmune ophthalmopathy from Graves? hyperthyroidism by analysis of genetic markers. Clin Endocrinol (Oxf ) 28:601-610.
58. Farid NR, Balazs C 1998 The genetics of thyroid associated ophthalmopathy. Thyroid 8:407-409.